New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors.
anticoagulants
factor XI
factor XII
venous thromboembolism
venous thrombosis
Journal
Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
medline:
26
10
2023
pubmed:
31
8
2023
entrez:
31
8
2023
Statut:
ppublish
Résumé
FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have the potential to be both more efficacious and safer than the currently available direct oral anticoagulants for the prevention and treatment of venous thromboembolism. In this review, we discuss the role of FXI and FXII in the pathogenesis of venous thromboembolism, explain why FXI is a better target, and explain why FXI inhibitors have potential advantages over currently available anticoagulants. Finally, we describe the FXI inhibitors under development and discuss their potential to address unmet needs in venous thromboembolism management.
Identifiants
pubmed: 37650326
doi: 10.1161/ATVBAHA.123.318781
doi:
Substances chimiques
Factor XI
9013-55-2
Anticoagulants
0
Factor XII
9001-30-3
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1755-1763Subventions
Organisme : CIHR
ID : FDN-159928
Pays : Canada